A carregar...
Publicação
COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 216.07 KB | Adobe PDF |
Orientador(es)
Resumo(s)
We estimated the effectiveness of 2024/25 COVID-19 vaccination against medically attended SARS-CoV-2 infection in Europe, among target groups. We included 3204 patients (8/139 cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a multicentre, test-negative design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34-85) overall, 73% (95% CI: 21-94) and 54% (95% CI: -3 to 83) in the first and second months post-vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33-86) among older adults (≥ 60 or ≥ 65 years). This relatively high COVID-19 VE (compared with previous seasons), as well as trends by time since vaccination, should be confirmed with additional data, as sample size was low.
Descrição
VEBIS Primary Care Vaccine Effectiveness Group: Portugal: Ausenda Machado, João Santos (Epidemiology Department, National Institute of Health Dr. Ricardo Jorge), Raquel Guiomar, Licínia Gomes, Camila Henriques and Daniela Dias (Infectious Disease Department, National Institute of Health Dr. Ricardo Jorge).
Palavras-chave
COVID‐19 SARS‐CoV‐2 Vaccine Effectiveness Europe Infecções Respiratórias Cuidados de Saúde
Contexto Educativo
Citação
Influenza Other Respir Viruses. 2025 May;19(5):e70120. doi: 10.1111/irv.70120
Editora
Wiley